NCT05005013CompletedPhase 2
A Teleheath tDCS Approach to Decrease Cannabis Use
A Teleheath tDCS Approach to Decrease Cannabis Use: Towards Reducing Multiple Sclerosis Disability
Source: ClinicalTrials.gov · Last updated 24 Jun 2025
Brief summary (registry, in English)
The study aims to evaluate the effect of Dorsolateral Prefrontal Cortex (DLPFC) Transcranial Direct Current Stimulation (tDCS) in decreasing distress and cannabis use. 46 participants with Relapse Remitting Multiple Sclerosis (RRMS), Cannabis Use Disorder (CUD) and elevated distress (K10 score of 10-35) will be recruited.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- First submitted
- 12 Aug 2021
- Start date
- 13 Sept 2022
- Primary completion date
- 14 Feb 2024
- Lead sponsor
- NYU Langone Health
- Diseases
- Multiple sclerosis
- NCT number
- NCT05005013
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 52
- From 13 Sept 2022 to the primary completion date, 14 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- MS clinical relapse or use of high dose of steroids in the past month
- Metal implants in the head or neck
- Enrolled in group or individual therapy for substance use disorder concurrent to intervention
Other illness
- Alcohol, tobacco, or substance use disorder other than cannabis
- Primary neurologic, psychiatric or other medical disorder other than MS (entry MD screening)
- Currently meets DSM-V criteria for moderate or severe substance use disorder in the past 6 months for any psychoactive substance.
- Meets DSM-V criteria for current panic disorder, obsessive-compulsive disorder, post-traumatic stress syndrome, bipolar affective disorder, schizophrenia, dissociate disorders, and any other psychotic disorder or organic mental disorder
- History of traumatic brain injury
- Any skin disorder or skin sensitive area near stimulation locations
Age
- Seizure disorder or recent (\<5 years) seizure history
Other
- Patients under medical marijuana use prescribed by a clinician
- Current suicidal ideation or deemed to be of potential risk of self-injury
- Pregnant or breastfeeding
Who the study is looking for
- Ages 21-65 (inclusive)
- Seeking treatment to reduce or discontinue current cannabis use (smoke/vape/ingest)
- Current Cannabis Use Disorder per DSM-V (MINI for DSM-V)
- K10 score 10-35, inclusive (mild to high moderate distress)
- Definite MS diagnosis, relapsing remitting (RRMS) subtype
- PDDS score 0-7 (mild to moderate neurological disability, established to be able to complete procedures)
- All medications stable for ≥ 1 month prior to enrollment and throughout the trial
- Ability to understand the informed consent process and provide consent to participate in the study
- Stable and continuous access to internet service, email (WiFi "hotspot" to be provided if needed)
- Ability to use mobile devices
- Fluent in English language (due to outcomes validated in English versions only)
- WRAT-4 score ≥ 85
Age in the registry: 21 years to 65 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NYU Langone Health Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.